Items tagged with Treatment
Glycemic changes common in patients with TB but no diabetes (post)
Glycemic changes may play an important role in response to treatment among patients with tuberculosis who do not have diabetes, according to data published in the American Journal of Respiratory Critical Care Medicine.
WHO issues rapid communication on updated guidance for the management of TB in children and adolescents (post)
26 August 2021 | Geneva - A rapid communication released by the World Health Organization (WHO) Global Tuberculosis Programme has announced important updates to guidance on the management of tuberculosis (TB) in children and adolescents. This includes new recommendations on diagnostic options, treatment regimens, as well as treatment decision algorithms and optimal models of care for the delivery of child and adolescent TB services.
RESIST-TB webinar on NeXT clinical trial (post)
On 23 September 2021, RESIST-TB will host a webinar to present the results of the recently-completed NeXT clinical trial for multidrug-resistant TB.
TB Alliance: Community engagement virtual forum - recording now available online (post)
On 12 August 2021, TB Alliance hosted a public webinar for community stakeholders to share details of the recently announced results from the ZeNix Phase 3 clinical trial. The trial revealed that the 6-month BPaL treatment regimen (bedaquiline, pretomanid and linezolid) remains effective against highly drug-resistant strains of TB with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.
TB Alliance and Lupin announce commercial partnership for new therapy for highly drug-resistant TB (post)
Agreement between non-profit product development partnership and multinational pharmaceutical company will expand access to new TB drug.
Hear us! Accounts of people treated with injectables for drug-resistant TB (post)
An article published in Public Health Action features testimonials from 14 TB survivors in 12 countries regarding their experiences with hearing loss from injectable-containing treatment regimens for drug-resistant TB.
EndTB clinical trial for multidrug-resistant TB completes enrolment (post)
BOSTON/PARIS, 18 October 2021 — Hundreds of patient volunteers from four continents have enrolled in a trial that aims to find safer, shorter, and effective treatments for multidrug-resistant tuberculosis (MDR-TB), an airborne, infectious disease that has grown resistant to standard medications. A group of scientists and clinicians led by Médecins Sans Frontières (MSF), Partners In Health (PIH) and Interactive Research and Development (IRD) make up the endTB consortium conducting the groundbreaking study funded by Unitaid.
MSF TB clinical trial finds shorter, more effective, and safer treatment (post)
New results show a much shorter treatment regimen for drug-resistant TB is superior to current options.
Highlights from the 52nd Union World Conference on Lung Health: Official press statements (post)
For the second year in a row, the 52nd Union World Conference on Lung Health was held virtually due to the COVID-19 pandemic on 19-22 October 2021 under the theme Lung Health for All: Solutions for a New Era. The Union World Conference is world’s largest gathering of clinicians and public health workers, health program managers, policymakers, researchers and advocates working to end the suffering caused by lung disease, with a focus specifically on the challenges faced by low- and lower-middle income populations.
Webinar on long-acting technologies (post)
On 4 November 2021, Treatment Action Group (TAG) and the International Treatment Preparedness Coalition (ITPC) will co-host a webinar, 'Same Meds, New Patents: What Do Activists Need to Know About Long-Acting Technologies', to present the main findings of the upcoming report 'Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis on Patenting Trends.'
Page 60 of 108 · Total posts: 0
←First 59 60 61 Last→